Compare · CRVO vs NVO
CRVO vs NVO
Side-by-side comparison of CervoMed Inc. (CRVO) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRVO and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $194.45B, about 4646.4x CRVO ($41.8M).
- Over the past year, CRVO is down 37.7% and NVO is down 43.4% - CRVO leads by 5.8 points.
- CRVO has been more active in the news (16 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 11 for CRVO).
- Company
- CervoMed Inc.
- Novo Nordisk A/S
- Price
- $4.52+78.66%
- $43.57-0.76%
- Market cap
- $41.8M
- $194.45B
- 1M return
- +29.51%
- -2.57%
- 1Y return
- -37.66%
- -43.43%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 16
- 4
- Recent ratings
- 11
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CRVO
- Wall Street Chases the Next Big Breakout
- Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum
- Director Boger Joshua S bought $3,000,000 worth of shares (955,414 units at $3.14) (SEC Form 4)
- CervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
- SEC Form 4 filed by Director Zavrl Frank
- SEC Form 4 filed by Director Sabbagh Marwan
- SEC Form 4 filed by Director Quigley David
- SEC Form 4 filed by Director Poulton Jeffrey V.
- SEC Form 4 filed by Director Hollingsworth Jane H
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S